Relative risks (RRs) (95% CIs) for low dose diuretics (LDDs) v placebo and other antihypertensive agents at mean 3–4 years*

OutcomesLDDs v placeboLDDs v β blockersLDDs v ACE inhibitorsLDDs v CCBsLDDs v ARBsLDDs v α blockers
*ACE  =  angiotensin converting enzyme; CCBs  =  calcium channel blockers; ARBs  =  angiotensin receptor blockers; CHD  =  coronary heart disease; CHF  =  congestive heart failure; CVD  =  cardiovascular disease. CI defined in glossary. All significant differences favour LDDs. RRs <1.0 favour LDDs; RRs >1.0 favour the alternative treatment.
†Statistically significant.
CHD0.79 (0.69 to 0.92)†0.87 (0.74 to 1.03)1.00 (0.88 to 1.14)0.89 (0.76 to 1.01)0.83 (0.59 to 1.16)0.99 (0.75 to 1.31)
CHF0.51 (0.42 to 0.62)†0.83 (0.68 to 1.01)0.88 (0.80 to 0.96)†0.74 (0.67 to 0.81)†0.88 (0.66 to 1.16)0.51 (0.43 to 0.60)†
Stroke0.71 (0.63 to 0.81)†0.90 (0.76 to 1.06)0.86 (0.77 to 0.97)†1.02 (0.91 to 1.14)1.20 (0.93 to 1.55)0.85 (0.66 to 1.10)
CVD events0.76 (0.69 to 0.83)†0.89 (0.80 to 0.98)†0.94 (0.89 to 1.00)0.94 (0.89 to 1.00)1.00 (0.85 to 1.18)0.84 (0.75 to 0.93)†
CVD mortality0.81 (0.73 to 0.92)†0.93 (0.81 to 1.07)0.93 (0.85 to 1.02)0.95 (0.87 to 1.04)1.07 (0.85 to 1.36)1.00 (0.75 to 1.34)
Total mortality0.90 (0.84 to 0.96)†0.99 (0.91 to 1.07)1.00 (0.95 to 1.05)1.03 (0.98 to 1.08)1.09 (0.96 to 1.22)0.98 (0.88 to 1.10)